Chick, J.B.

patient osi -7836 -7836 study infusion cancer minute gemcitabine schedule grade fatigue range toxicity phase treatment cycle tumor plasma antitumor activity phase i study lymphocyte analysis cytokine subset activity level administration lymphocyte subset analysis dosing 60- minute infusion 100 mg /m sample count table increase day 1 response baseline nucleoside 21 days elimination 5- minute infusion pharmacokinetic half-life assessment toxicitie blood lymphocyte subsets 60- antitumor number elimination half-life analogue cancer institute dose level 400 mg /m 1/2 phase ii study 200 mg /m difference therapy clearance www.aacrjournals.org il -6 plasma clearance cohort b lymphocytes symptom 24 hours blood samples thio-ara-u 4 weeks event nucleoside analogues lymphocytes urine samples urine effect elevation z 7 days